Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.Cmvv_fHs.js ...
The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Eli Lilly, Novo Nordisk, and Amgen all look cheap. All of them could experience a massive boost to profits in the years to ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...